ORPHA:180242
Malignant tumor of fallopian tubes
Also known as: Cancer of fallopian tubes · Malignant tubal tumor · Tubal cancer
Publications
4,580
92.3th percentile
Trials
561
Interventional, condition-specific
Researchers
1,433
Distinct authors in sample
Gene link
—
Readiness
3/6
Stages with a signal
How rare: 1-9 / 100 000 — about one to nine people per hundred thousand.
Cross-references
Joined from Mondo / Orphanet. MeSH labels may enter searches; UMLS / OMIM / NCIT are stored for reference.
- MONDO:0002158
- UMLS:C0153579
- NCIT:C7480
Additional Mondo synonyms (22)
cancer of fallopian tube · cancer of fallopian tubes · fallopian tube cancer · fallopian tube malignant neoplasm · fallopian tube malignant tumor · fallopian tube malignant tumour · malignant fallopian tube neoplasm · malignant fallopian tube tumor · malignant fallopian tube tumour · malignant neoplasm of fallopian tube · malignant neoplasm of the fallopian tube · malignant neoplasm of uterine tube · malignant tubal tumor · malignant tubal tumour · malignant tumor of fallopian tube · malignant tumor of fallopian tubes · malignant tumor of the fallopian tube · malignant tumour of fallopian tubes · malignant tumour of the fallopian tube · neoplasm, fallopian tube, malignant · tubal cancer · tumor, fallopian tube, malignant
Research stages
Trial readiness signals
Where this condition sits on an open-data research pipeline — not how close a treatment is, and not medical advice. Empty stages often mean “not in these databases under this Mondo ID,” not “impossible.”
3/6 stages with a signal
An interventional trial matched this condition name on ClinicalTrials.gov — see trials below.
- Gene identifiedNot found
No GenCC disease–gene assertion in this build
- LiteraturePresent
4,580 matched papers (3,100 in last 10 years) Source
- Phenotype characterisedNot found
No HPO disease–phenotype associations via Monarch for these Mondo IDs
- Animal modelNot found
No Alliance genotype “model of” associations via Monarch for these Mondo IDs
- Orphan designationPresent
3 FDA · 1 EMA designations (2 FDA orphan-indication approvals) — e.g. pelareorep Source
- Interventional trialPresent
561 matched on ClinicalTrials.gov (59 recruiting in sample)
Biology
Genes and phenotypes
Gene–disease validity from GenCC, plus phenotypes and animal models joined from Monarch Initiative via Mondo ID — not a clinical diagnosis aid.
Do we know what causes it?
Not yet — the cause hasn't been pinned down in GenCC.
No strong gene–disease assertion joined for this Orphanet entity.
Phenotypes (Monarch / HPO)
None returned for this Mondo ID. That often means “not linked under this ID,” not “no clinical features.”
Animal models (Monarch / Alliance)
None returned for this Mondo ID. Empty here is not proof that no model organism work exists under another name or gene.
Monarch fetch 2026-07-29
Therapies
Designations, candidates, and chemicals
FDA OOPD and EMA orphan designations, Open Targets clinical candidates, and CTD chemical associations via MyDisease.info. These never change the interventional-trial headline.
Orphan designation (FDA · EMA)
4
Designations · 2 with FDA orphan-indication approval
- FDA pelareorepFallopian Tube Cancer · 2015-02-24 · Not FDA Approved for Orphan Indication
- FDA patupiloneFallopian Tube Cancer · 2010-02-02 · Not FDA Approved for Orphan Indication
- FDA olaparib (Lynparza)Fallopian Tube Cancer · 2018-05-15
- EMA patupiloneTreatment of fallopian tube cancer · 05/11/2009 · WithdrawnEMA designation
Sources: FDA OOPD · EMA orphan designations
Open Targets candidates
237
Drugs / clinical candidates · MONDO_0002158
- ATEZOLIZUMAB·phase 3
- AVELUMAB·phase 3
- AZENOSERTIB·phase 3
- BEVACIZUMAB·phase 3
- CANFOSFAMIDE·phase 3
- CANFOSFAMIDE HYDROCHLORIDE·phase 3
- CARBOPLATIN·phase 3
- CEDIRANIB·phase 3
- CISPLATIN·phase 3
- CYCLOPHOSPHAMIDE·phase 3
- DOCETAXEL·phase 3
- DOSTARLIMAB·phase 3
- DOXORUBICIN·phase 3
- DOXORUBICIN HYDROCHLORIDE·phase 3
- DURVALUMAB·phase 3
CTD chemicals (MyDisease.info)
No CTD chemical associations returned for this Mondo ID.
Literature
Is anyone studying this?
4,580
4,580 papers have been published on this condition. That is a real research literature — still far smaller than common diseases (breast cancer: over 700,000 papers). Median papers in the last 10 years for a rare disease in this dataset (publications denominator n=3967) is 59.
4,580 papers since the earliest indexed year in this search — median last-10-year count for a rare disease in this dataset is 59 (publications denominator n=3967).
3,100 in the last 10 years · high confidence · 92.3th percentile (publications denominator)
Phrase hits: 4,580 · MeSH hits: 0
Who's working on it?
1,433
Distinct author names in 200 sampled papers — named people below.
Who's working on it?
People publishing on this condition (sampled Europe PMC records). Affiliation is the most recent found in that sample.
- 01Wang Y10 papers · 2026
Department of Obstetrics and Gynecology, Kaohsiung Chang Gung Memorial Hospital, Kaohsiung City 833, Taiwan.
Papers in Europe PMC - 02Li Y9 papers · 2026
Department of Assisted Reproductive Centre, The affiliated Zhuzhou hospital Xiangya medical college, Central South University, Zhuzhou, Hunan, China.
Papers in Europe PMC - 03Chen X7 papers · 2026
Department of Epidemiology and Statistics, School of Public Health, Medical College, Zhejiang University, Hangzhou, Zhejiang, China.
Papers in Europe PMC - 04Chen Y5 papers · 2025
Department of Gynecological Oncology, Tianjin Medical University Cancer Institute & Hospital, Tianjin, People's Republic of China.
Papers in Europe PMC - 05Liu H5 papers · 2025
Department of Gynecology, Dongzhimen Hospital of Beijing University of Chinese Medicine, Beijing, China.
Papers in Europe PMC - 06Liu Y4 papers · 2026
Department of Gynecological Oncology, Beijing Obstetrics and Gynecology Hospital, Capital Medical University, Beijing Maternal and Child Health Care Hospital, Beijing 100006, China.
Papers in Europe PMC - 07Ma Y4 papers · 2026
Department of Pathology, The Fourth Affiliated Hospital of School of Medicine, and International School of Medicine, International Institutes of Medicine, Zhejiang University, Yiwu, China.
Papers in Europe PMC - 08Zhou J4 papers · 2024
Department of Obstetrics and Gynecology, The Second Affiliated Hospital, Hengyang Medical School, University of South China, Hengyang, Hunan, China.
Papers in Europe PMC - 09Chan JK3 papers · 2026
Division of Gynecologic Oncology, Palo Alto Medical Foundation, California Pacific Medical Center, Sutter Health, San Francisco, CA, USA.
Papers in Europe PMC - 10Colombo N3 papers · 2025
European Institute of Oncology IRCCS Library, Milan, Italy.
Papers in Europe PMC
Clinical research
Is a treatment being tested?
561
interventional trials for this specific condition
561 interventional trials matched this specific condition name; 59 currently recruiting in our sample.
Data as of 11 September 2026
561 interventional trials — more than 77.2% of diseases in the trials denominator have none at all (5501 of 7126; this disease is at the 99.7th percentile).
high confidence · 99.7th percentile (trials denominator)
Recruiting interventional trials
From the matched ClinicalTrials.gov set
561 interventional trials matched after quoted-phrase search and title/condition post-filter.
- NCT05659381·RECRUITING·Heated Intraperitoneal Chemotherapy Followed by Niraparib for Ovarian, Primary Peritoneal and Fallopian Tube Cancer
Not reviewed·Conditions: Stage III Ovarian Cancer · Stage IV Ovarian Cancer · Stage III Primary Peritoneal Cancer · Stage IV Primary Peritoneal Cancer·Matched via name phrase
- NCT07708753·NOT YET RECRUITING·A Study of SYS6043 in Platinum-Resistant, Advanced Ovarian, Primary Peritoneal, or Fallopian Tube Cancers
Not reviewed·Conditions: Platinum-resistant Ovarian Cancer · Platinum-resistant Primary Peritoneal Cancer · Platinum-resistant Fallopian Tube Cancer·Matched via name phrase
- NCT06602063·NOT YET RECRUITING·Surgery for Relapsed Ovarian Cancer in Precision
Not reviewed·Conditions: Epithelial Ovarian Cancer · Fallopian Tube Cancer · Primary Peritoneal Carcinoma·Matched via name phrase
- NCT06735326·RECRUITING·Fluzoparib With or Without Bevacizumab for Neoadjuvant Therapy in Advanced Ovarian Cancer
Not reviewed·Conditions: Ovarian Cancer · Fallopian Tube Cancer · Peritoneal Cancer·Matched via name phrase
- NCT07023484·RECRUITING·Personalized Timing of Interval Debulking Surgery in Advanced Ovarian Cancer
Not reviewed·Conditions: Ovarian Cancer · Fallopian Tube Cancer · Primary Peritoneal Carcinoma·Matched via name phrase
- NCT06617923·RECRUITING·Study of Senaparib in Combination With Temozolomide in ARID1A Mutation Associated Ovarian Cancer
Not reviewed·Conditions: Ovary Cancer · Fallopian Tube Cancer · Primary Peritoneal Cavity Cancer·Matched via name phrase
- NCT06690775·RECRUITING·CATALINA-2: A Clinical Study of TORL-1-23 in Platinum-resistant Ovarian Cancer.
Not reviewed·Conditions: Epithelial Ovarian Cancer · Primary Peritoneal · Fallopian Tube Cancer · Endometrioid Ovarian Cancer·Matched via name phrase
- NCT07586826·RECRUITING·Romiplostim N01 Plus ATRA for Persistent Isolated Chemotherapy-Induced Thrombocytopenia After Complete Remission of Gynecologic, Breast, or Lung Solid Tumors
Not reviewed·Conditions: Persistent Isolated Chemotherapy-Induced Thrombocytopenia · Chemotherapy-Induced Thrombocytopenia · Gynecologic Cancers · Ovarian Cancer·Matched via name phrase
- NCT06890338·RECRUITING·A Study to Assess Anti-Tumor Activity of Intravenously (IV) Infused Carboplatin With Mirvetuximab Soravtansine in Participants With Newly Diagnosed Folate Receptor Alpha (FRα)Expressing Advanced-Stage Serous Epithelial Ovarian, Fallopian Tube or Primary Peritoneal Cancer.
Not reviewed·Conditions: Epithelial Ovarian Cancer · Fallopian Tube Cancer · Primary Peritoneal Cancer · Neoadjuvant·Matched via name phrase
- NCT06787612·RECRUITING·Investigation of Ubamatamab Combination Therapy in Adult Participants With Platinum-Resistant Ovarian Cancer
Not reviewed·Conditions: Ovarian Cancer · Fallopian Tube Cancer · Primary Peritoneal Cancer·Matched via name phrase
- NCT04701645·RECRUITING·Microdevice In Ovarian, Fallopian Tube, And Peritoneal Cancer
Not reviewed·Conditions: Ovarian Cancer · Fallopian Tube Cancer · Peritoneal Cancer · Ovarian Cancer Stage III·Matched via name phrase
- NCT06824467·RECRUITING·A Study to Evaluate the Efficacy and Safety of Sacituzumab Tirumotecan (MK-2870) Maintenance Treatment Versus Standard of Care in Participants With Platinum-sensitive Recurrent Ovarian Cancer (MK-2870-022/TroFuse-022/ENGOT-ov84/GOG-3103)
Not reviewed·Conditions: Ovarian Cancer · Fallopian Tube Cancer · Primary Peritoneal Cancer·Matched via name phrase
- NCT03968406·RECRUITING·Talazoparib and Radiation Therapy in Treating Patients With Locally Recurrent Gynecologic Cancers
Not reviewed·Conditions: Malignant Female Reproductive System Neoplasm · Recurrent Cervical Carcinoma · Recurrent Endometrial Carcinoma · Recurrent Fallopian Tube Carcinoma·Matched via name phrase
- NCT04516447·RECRUITING·A Study of Azenosertib (ZN-c3) in Patients With Ovarian Cancer
Not reviewed·Conditions: Solid Tumor · Epithelial Ovarian Cancer · Fallopian Tube Cancer · Peritoneal Cancer·Matched via name phrase
- NCT06290193·RECRUITING·Study of Acute Normovolemic Hemodilution (ANH) in People With Ovarian Cancer Who Are Having Cytoreductive Surgery
Not reviewed·Conditions: Ovarian Cancer · Fallopian Tube Carcinoma · Ovarian Carcinoma · Peritoneal Carcinoma·Matched via name phrase
Observational and natural-history studies
59 observational studies match this condition. These do not test a treatment and are not counted in the interventional-trial headline, but they are genuine research: natural-history work often defines the endpoints needed for a future rare-disease trial, and families may be able to enroll.
Recruiting or not-yet-recruiting
- NCT07687602·NOT YET RECRUITING·A Study to Evaluate Adverse Events and Change in Disease Activity of Mirvetuximab Soravtansine-gynx in Adults With Folate Receptor-Alpha Positive, Platinum-Resistant Ovarian Cancer in a Real-World Setting
Not reviewed·Conditions: Folate Receptor-Alpha Positive Platinum-Resistant High-Grade Serous Epithelial Ovarian Cancer · Folate Receptor-Alpha Positive Platinum-Resistant Fallopian Tube Cancer · Folate Receptor-Alpha Positive Platinum-Resistant Primary Peritoneal Cancer·Matched via name phrase
- NCT06010667·NOT YET RECRUITING·A Prospective, Randomized Controlled Study of Cyclophosphamide, Bevacizumab With or Without Envafolimab in Recurrent Epithelial Ovarian Cancer (EOC), Fallopian Tube Cancer, and Primary Peritoneal Cancer
Not reviewed·Conditions: Epithelial Ovarian Cancer·Matched via name phrase
- NCT06024109·RECRUITING·Performance of SYMMCORA® vs. V-Loc® Suture Material in Patients Undergoing Laparoscopic Total Hysterectomy
Not reviewed·Conditions: Abnormal Uterine Bleeding · Endometriosis · Uterine Prolapse · Uterine Cancer·Matched via name phrase
- NCT05912972·RECRUITING·Development and Management of Registry in Patients With Gynecologic Cancer in Korea
Not reviewed·Conditions: Cervical Cancer · Endometrial Cancer · Ovarian Cancer · Fallopian Tube Cancer·Matched via name phrase
- NCT00005095·RECRUITING·Specimen and Data Study for Ovarian Cancer Early Detection and Prevention
Not reviewed·Conditions: Cervical Cancer · Endometrial Cancer · Fallopian Tube Cancer · Hereditary Breast/Ovarian Cancer (brca1, brca2)·Matched via name phrase
- NCT05574673·RECRUITING·Characterization of Epithelial Ovarian Cancer Patients in Terms of Homologous Recombination Phenotype
Not reviewed·Conditions: Ovarian Cancer · Primary Peritoneal Cancer · Fallopian Tube Cancer·Matched via name phrase
- NCT07667192·RECRUITING·Reirradiation and Total Ablative Strategies for Recurrent Gynecologic Cancer
Not reviewed·Conditions: Recurrent Gynecologic Cancer · Recurrent Uterine Cancer · Recurrent Cervical Cancer · Recurrent Vaginal Cancer·Matched via name phrase
Other registries (secondary)
Broader net from EU CTIS, ISRCTN, and ICTRP when available — deduped against ClinicalTrials.gov IDs already counted above. Dual-model LLM relevance gates what we keep. These rows are not added to the interventional headline.
raw 14 · after dedupe 14 · already on CT.gov 0 · kept 0 · parent 0 · uncertain 14 · dropped 0 · fetched 2026-07-30
Source notes: ictrp: Error: ICTRP public search unavailable (WHO portal is SPA-only; SOAP needs partnership). Tried: https://apps.who.int/tri
No secondary-registry studies passed dual-model relevance for this condition name (after dedupe).
Uncertain / not reviewed (14)
- isrctn·ISRCTN42408038·No longer recruiting·Can cytology replace tumor tissue in determining somatic mutations of BRCA 1/2 genes in patients with epithelial carcinoma of ovaries, fallopian tubes or peritoneal serous carcinoma?
skipped — LLM skipped (--skip-llm)
- isrctn·ISRCTN13720638·Recruiting·Safety and tolerability of APL-3007 administered as a single dose in addition to background therapy with a C5 inhibitor in adults with paroxysmal nocturnal hemoglobinuria
skipped — LLM skipped (--skip-llm)
- isrctn·ISRCTN17289436·Recruiting·A population-based digital study offering people testing for cancer genes, to identify people at increased risk of cancer so they can take steps to prevent it or detect it early
skipped — LLM skipped (--skip-llm)
- isrctn·ISRCTN33767504·No longer recruiting·Does removing both ovaries prior to menopause reduce breast cancer risk in BRCA1 and BRCA2 mutation carriers?
skipped — LLM skipped (--skip-llm)
- isrctn·ISRCTN28449692·No longer recruiting·Phase II study of roginolisib in uveal melanoma patients
skipped — LLM skipped (--skip-llm)
- isrctn·ISRCTN30841680·No longer recruiting·A blinded study in healthy volunteers to evaluate the safety of the test medicine and compare how the test medicine behaves when the dosage is increased, and when taken alone or alongside salbutamol (albuterol)
skipped — LLM skipped (--skip-llm)
- isrctn·ISRCTN41671021·No longer recruiting·Avoiding late diagnosis of ovarian cancer
skipped — LLM skipped (--skip-llm)
- isrctn·ISRCTN25173360·Suspended·Early removal of Fallopian tubes and delayed removal of ovaries in women at high risk of ovarian cancer
skipped — LLM skipped (--skip-llm)
- isrctn·ISRCTN12310993·No longer recruiting·Views of women at increased risk of ovarian cancer towards removal of fallopian tubes for ovarian cancer prevention
skipped — LLM skipped (--skip-llm)
- isrctn·ISRCTN67795930·No longer recruiting·A trial designed to treat women with a diagnosis of ectopic pregnancy with a combination of methotrexate (standard treatment) and gefitinib (trial agent)
skipped — LLM skipped (--skip-llm)
- isrctn·ISRCTN12509361·No longer recruiting·BRAVO Study: Surgery vs. Immunotherapy – Which treatment is best in bladder cancer?
skipped — LLM skipped (--skip-llm)
- isrctn·ISRCTN14782577·No longer recruiting·The role of an intraoperative intraperitoneal chemotherapy after neoadjuvant chemotherapy in patients with advanced (stage IIIC) epithelial ovarian cancer
skipped — LLM skipped (--skip-llm)
- isrctn·ISRCTN26261491·No longer recruiting·A pilot randomised controlled trial to evaluate the utility and efficacy of neutral argon plasma (PlasmaJet®) as a new technology in achieving complete debulking of advanced Epithelial Ovarian Cancer
skipped — LLM skipped (--skip-llm)
- isrctn·ISRCTN96797814·No longer recruiting·The PROOF trial: PROtecting Ovaries and Fertility during chemotherapy
skipped — LLM skipped (--skip-llm)
Where to find support
Condition-specific patient organisations, when Orphanet lists them, are on the disease’s Orphanet page. We also link umbrella groups that support undiagnosed and ultra-rare families.
Orphanet entry for Malignant tumor of fallopian tubes — check Associations / patient organisations on that page.
India — NPRD
Last verified 2026-07-26This ORPHAcode is not on our curated NPRD list (direct or Mondo-parent match). That does not decide clinical eligibility; families in India should ask a notified Centre of Excellence about current coverage.
Hand-curated for this project. ORPHAcode mappings are best-effort and may be incomplete or imprecise for umbrella categories. Parent (Mondo) matches mean the policy lists a broader category — confirm eligibility with a Centre of Excellence. Financial entitlements summarised from public policy statements and may change. This is not official government guidance.
How we counted this
Europe PMC query (preferred label + any corrected label + Orphanet and Mondo exact synonyms, stoplisted; unioned with resolved MeSH labels when available). UMLS / OMIM / NCIT cross-references are stored on the overview but are not added to the query string.
"Malignant tumor of fallopian tubes" OR "Malignant tumor of the fallopian tubes" OR "Cancer of fallopian tubes" OR "Cancer of the fallopian tubes" OR "Malignant tubal tumor" OR "Tubal cancer" OR "cancer of fallopian tube" OR "cancer of the fallopian tube" OR "fallopian tube cancer" OR "fallopian tube malignant neoplasm" OR "fallopian tube malignant tumor" OR "fallopian tube malignant tumour" OR "malignant fallopian tube neoplasm" OR "malignant fallopian tube tumor" OR "malignant fallopian tube tumour" OR "malignant neoplasm of fallopian tube" OR "malignant neoplasm of the fallopian tube" OR "malignant neoplasm of uterine tube" OR "malignant neoplasm of the uterine tube" OR "malignant tubal tumour" OR "malignant tumor of fallopian tube" OR "malignant tumor of the fallopian tube" OR "malignant tumour of fallopian tubes" OR "malignant tumour of the fallopian tubes" OR "malignant tumour of the fallopian tube" OR "malignant tumour of fallopian tube" OR "neoplasm, fallopian tube, malignant" OR "tumor, fallopian tube, malignant"
ClinicalTrials.gov query (quoted phrases + MeSH via query.cond, plus recall-expansion terms when used):
"Malignant tumor of fallopian tubes" OR "Malignant tumor of the fallopian tubes" OR "Cancer of fallopian tubes" OR "Cancer of the fallopian tubes" OR "Malignant tubal tumor" OR "Tubal cancer" OR "cancer of fallopian tube" OR "cancer of the fallopian tube" OR "fallopian tube cancer" OR "fallopian tube malignant neoplasm" OR "fallopian tube malignant tumor" OR "fallopian tube malignant tumour" OR "malignant fallopian tube neoplasm" OR "malignant fallopian tube tumor" OR "malignant fallopian tube tumour" OR "malignant neoplasm of fallopian tube" OR "malignant neoplasm of the fallopian tube" OR "malignant neoplasm of uterine tube" OR "malignant neoplasm of the uterine tube" OR "malignant tubal tumour" OR "malignant tumor of fallopian tube" OR "malignant tumor of the fallopian tube" OR "malignant tumour of fallopian tubes" OR "malignant tumour of the fallopian tubes" OR "malignant tumour of the fallopian tube" OR "malignant tumour of fallopian tube" OR "neoplasm, fallopian tube, malignant" OR "tumor, fallopian tube, malignant"
Interventional trials matched via: phrase (mesh = registered under a MeSH descriptor no name phrase would catch; recall-expansion = gene / selected parent terms used only for trials).
Study-type breakdown: 561 interventional · 59 observational · 0 expanded access. Only interventional studies enter the trial headline.
Query health: ok — strategies attempted: phrase; with hits: phrase
Run this search on ClinicalTrials.gov
Confidence reasoning
- Preferred label is multi-word and distinctive
- No synonyms dropped by stoplist
- No label/synonym collisions with other diseases in this corpus
Ingested 2026-07-27T09:04:15.261Z
